Investigation of cancer therapeutic method without side effects: Suppression mechanisms of cancer metastasis on the lung by CXCL14/BRAK
| Project/Area Number |
25293384
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pathobiological dentistry/Dental radiology
|
|---|
| Research Institution | Kanagawa Dental College |
|---|
Principal Investigator |
Hata Ryu-Ichiro 神奈川歯科大学, 歯学研究科(研究院), その他 (10014276)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MAEHATA YOJIROU 神奈川歯科大学, 大学院歯学研究科, 講師 (80410009)
IZUKURI KAZUHITO 神奈川歯科大学, 大学院歯学研究科, 講師 (90257296)
AKASAKA TETSU 神奈川歯科大学, 大学院歯学研究科, 助教 (60316263)
MIYAMOTO CHIHIRO 神奈川歯科大学, 大学院歯学研究科, 特別研究員 (50633963)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TAKEDA KAZUYOSHI 順天堂大学, 大学院医学研究科, 准教授 (80272821)
MUKAIDA NAOFUMI 金沢大学, がん伸展制御研究所, 教授 (30182067)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2014: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2013: ¥12,090,000 (Direct Cost: ¥9,300,000、Indirect Cost: ¥2,790,000)
|
|---|
| Keywords | 癌抑制分子 / ケモカイン / 転移抑制 / 副作用のない癌抑制法 / 余命の延長 / がん抑制分子 / 多段階がん抑制性ケモカイン / 多機能がん抑制性ケモカイン / ケモカインCXCL14 / CXCL14 / ケモカインCXCL14/BRAK / 発癌抑制 / 寿命の延長 |
|---|
| Outline of Final Research Achievements |
The main cause of Japanese death is due to the recurrence of cancer, and metastasis. We have previously reported that the rate of carcinogenesis, the growth of tumor transplants and metastasis in CXCL14 over-expressed transgenic (Tg) mouse were significantly lower compared with that for isogenic wild type C57BL/6 (Wt) mice. Here we investigated suppression mechanisms of metastasis by CXCL14 using the pulmonary metastasis system of the malignant melanoma cell and the cell culture system. It was found that CXCL14 and interferon-γ (IFN-γ) secreted by the activated natural killer (NK)T cells, and also IFN-γ secreted by activated natural killer cells synergistically suppressed the metastasis of the cells on the lungs.
|
Report
(4 results)
Research Products
(34 results)
-
[Journal Article] Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma2016
Author(s)
Tadanori Kondo, Shigeyuki Ozawa, Takeharu Ikoma, Xiao-Yan Yang, Keisuke Kanamori, Kenji Suzuki, Hiroshi Iwabuchi, Yojio Maehata, Chihiro Miyamoto, Takahide Taguchi, Tohru Kiyono, Eiro Kubota, and Ryu-Ichiro Hata
-
Journal Title
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Journal Article] Chemokine CXCL14 is a multistep tumor suppressor.2016
Author(s)
Xiao-Yan Yang, Chihiro Miyamoto, Tetsu Akasaka, Kazuhito Izukuri, Yojiro Maehata, Takeharu Ikoma, Shigeyuki Ozawa, Ryu-Ichiro Hata
-
Journal Title
Journal of Oral Biosciences
Volume: 58
Issue: 1
Pages: 16-22
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
[Journal Article] Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice.2015
Author(s)
Hata R, Izukuri K, Kato Y, Sasaki S, Mukaida N, Maehata Y, Miyamoto C, Akasaka T, Yang X, Nagashima Y, Takeda K, Kiyono T, Taniguchi M.
-
Journal Title
Scientific Reports
Volume: 5
Issue: 1
Pages: 9083-9083
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] <b>Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell car</b><b>cinoma </b>2014
Author(s)
Miyamoto C., Maehata Y, Motohashi K, Ozawa S, Ikoma T, Hidaka K, Wada-Takahashi S, Yoshino F, Yoshida A, Kubota E, Hata R, Lee M.C
-
Journal Title
Biomedical Research
Volume: 35
Issue: 6
Pages: 381-388
DOI
NAID
ISSN
0388-6107, 1880-313X
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
[Presentation] EXPRESSION OF THE CHEMOKINE CXCL14 IS A PREDICTIVE BIOMARKER FOR CETUXIMAB-DEPENDENT TUMOUR SUPPRESSION2015
Author(s)
Ryu-Ichiro Hata, Tadanori Kondo, Shigeyuki Ozawa, Takeharu Ikoma, Kenji Suzuki, Hiroshi Iwabuchi, Yojiro Maehata, Chihiro Miyamoto, Xiaoyan Yang, Eiro Kubota
Organizer
st Nature Immunology - Cellular & Molecular Immunology Joint Conference
Place of Presentation
Hefei, China
Year and Date
2015-06-17
Related Report
Int'l Joint Research
-
-
-
[Presentation] Chemokine CXCL14 is a multistep tumor suppressor.2015
Author(s)
Ryu-Ichiro Hata, Kazuhito Izukuri, Yasumasa Kato, Soichiro Sasaki, Chihiro Miyamoto, Tetsu Akasaka, Xiaoyan Yang, Yojiro Maehata, Yoji Nagashima, Kazuyoshi Takeda, Tohru Kiyono, Naofumi Mukaida, Masaru Taniguchi
Organizer
2015 American Association of Cancer Research Annual Meeting
Place of Presentation
Philadelphia
Year and Date
2015-04-18
Related Report
Int'l Joint Research
-
-
-
-
-
[Presentation] ROCK specific inhibitor fasudil suppresses head and neck squamous carcinoma growth by stimulating gene expression and protein secretion of the CXCL14/BRAK,2014
Author(s)
Miyamoto C, Ozawa T, Ikoma T, Wada-Takahashi S, Takahashi S-S, Yoshida A, Yoshino F, Hata R, Lee M-C, Maehata Y,
Organizer
FEBS-EMBO 2014 Conference,
Place of Presentation
Paris, France
Year and Date
2014-08-30 – 2014-09-04
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
